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Abstract – Objective: To describe clinical and neuroimaging (SPECT) characteristics of Brazilian patients with 
Parkinson’s disease (PD) and mutations in PARK2 or PARK8 genes.  Method: A total of 119 patients meeting 
clinical criteria for PD were evaluated.  Results: Of all patients studied, 13 had mutations in either PARK2 (n=9) 
or PARK8 genes (n=4). No statistically significant differences in clinical characteristics in both groups were 
seen. SPECT with [99mTc] TRODAT-1 showed significant differences between patient and control and the most 
remarkable difference was between PARK2 and control.  Conclusion: The study found a frequency of mutation 
of 10.1% and it was most commonly seen in women. These patients had long disease course and high rates of 
dyskinesia after L-DOPA use. PARK8 patients did not have a relevant family history of PD.
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Características clínicas e de neuroimagem molecular de pacientes brasileiros com doença de parkinson e 
mutações nos genes PARK2 ou PARK8
Resumo – Objetivo: Descrever as características clínicas e de neuroimagem (SPECT) de pacientes brasileiros com 
doença de Parkinson e mutações PARK2 e PARK8.  Método: Foram avaliados 119 pacientes com critérios clínicos 
para a doença de Parkinson.  Resultados: Entre os pacientes avaliados foram encontrados 13 pacientes com 
mutação nos genes PARK2 (n=9) ou PARK8 (n=4). Não houve diferença significativa na avaliação das características 
clínicas entre os dois grupos. Os resultados de SPECT mostraram diferenças significativas quanto ao potencial de 
ligação do [99mTc] TRODAT-1 SPECT entre pacientes vs. controle, sendo a diferença mais pronunciada entre PARK2 
e controle.  Conclusão: A freqüência de mutação encontrada foi 10,1%, sendo mais comum em mulheres. Estes 
pacientes apresentavam longo tempo de doença e alta prevalência de discinesias associadas ao uso da levodopa. 
Nossos pacientes com PARK8 não apresentaram uma história familiar relevante de doença de Parkinson.
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Parkinson’s disease (PD) is a chronic neurodegenerative 
disease affecting mostly patients over the age of 50 (late-
onset PD or LOPD) and it has a prevalence of 1 to 3% in pa-
tients in their seventies or more1. PD is characterized by 
motor and non-motor symptoms that first develop as a re-
sult of loss of dopaminergic neurons in the substancia nigra 
pars compacta in the mesencephalon. As for its etiology, it 
has been proposed a complex interaction between environ-
mental and toxic factors, genetic predisposition and age2,3. 
PD pathogenesis may involve dysfunction of protea-
some-ubiquitin and mitochondrial system that triggers a 
cascade of events leading to dopaminergic loss, which is 
a distinctive trait of this disease4. Environmental factors 
including well water drinking, living in rural areas, expo-
sure to pesticides, herbicides and organic solvents have 
been implicated in the etiology of PD5.
We describe the main clinical findings of Brazilian 
patients with genetically defined PD with mutations in 
PARK2 or PARK8 genes as well as some molecular neu-
roimaging findings. 
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method
Patient recruitment
There were 119 patients selected, both males and females 
of all age groups, clinically diagnosed with PD with or without 
family history and whose diagnosis was made according to the 
London Brain Bank criteria6. Although age was not considered a 
limiting criterion, we chose to include in the study patients with 
early-onset PD (EOPD), i.e., patients who developed their first PD 
symptoms before the age of 50. This choice was based on the 
fact that genetic PD cases would be more likely to be detected. 
The recruitment occurred between 2006 and 2008.
Patients were clinically evaluated by the study team and se-
lected among those seen at UNIFESP/EPM Division of Move-
ment Disorders and at the authors’ (LAFA and OGPB) private of-
fices. After signing a free informed consent form, patients were 
assessed through a structured medical evaluation using the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) (patients during 
“on” state) and Hohen and Yahr scale. In addition, 20 mL blood 
sample was drawn through peripheral venipuncture for genet-
ic testing. Patients who did not meet the diagnostic criteria for 
PD were excluded from the study.
Clinical data 
The following clinical data were assessed: gender; age at 
symptom onset; age at current evaluation; disease course; fam-
ily history of PD; consanguinity; risk factors for PD; site of first 
symptom; first symptom; L-DOPA use; and L-DOPA-induced dys-
kinesia. Exposure to potential environmental risk factors (living 
in rural areas, well water drinking, exposure to pesticides, herbi-
cides and organic solvents and smoking) was defined as house-
hold contact or occupational exposure to a given factor for at 
least two continuous years on a regular basis, at a minimum fre-
quency of one day per month before disease onset. 
Mutation analysis
Genomic DNA was extracted from peripheral whole blood 
using the Puregene® DNA Purification kit (Gentra Systems) or 
cheek swab using the ChargeSwitch gDNA Buccal Cell kit® (In-
vitrogen). DNA was amplified by PCR (primers and conditions 
available upon request). All 12 PARK2 exons and exon-intron 
boundaries (GenBank NM_004562) were screened by standard 
dideoxy nucleotide sequencing on a MegaBACE 1000 DNA Se-
quencer (Amersham Biosciences) and gene dosage studies were 
performed by real-time fluorescence based quantitative PCR on 
a ABI 7300 Sequence detector system (Applied Biosystems) us-
ing TaqMan® fluorescently labeled probes 5’FAM or VIC (Assays-
by-Design, Applied Biosystems) and TaqMan® PCR Master Mix 
(Applied Biosystems). Relative quantification was performed 
with duplex PCR in triplicates using the single copy human Beta 
globin gene as internal control (primers, probes and conditions 
available upon request). A standard curve was generated for each 
PARK2 exon and for Beta globin with serial dilutions of a control 
DNA with known concentration. Sample concentrations were 
inferred based on this regression curve, and a relative PARK2/
Beta globin ratio was obtained for each sample. Concentrations 
not within the range of the standard templates were disregard-
ed. A normal control sample was used in all reactions. PARK2/
Beta globin ratios below 0.7 or above 1.3 were considered as 
deletions or duplications, respectively. All detected gene dos-
age variations were confirmed at least twice. PARK8 (GenBank 
AY792511) L1114L, I1122V, R1441C, Y1699C and G2019S mutations 
were screened by direct sequencing. SNPs identified in patients 
were screened in 144 control chromosomes either by denatur-
ing high performance liquid chromatography (DHPLC) using the 
WAVE® Nucleic Acid Fragment Analysis System (Transgenomic, 
Omaha, NE), or by direct sequencing7.
Imaging procedures and analysis
SPECT scans were performed with [99mTc]-TRODAT-1, a ra-
diotracer with high selectivity and specificity for the Dopamine 
Transporter (DAT). TRODAT-1 kits were produced by the Insti-
tute of Nuclear Energy Research (INER-Taiwan R.O.C.). Images 
were acquired four hours after the injection of 814MBq (±74) of 
[99mTc]-TRODAT-1. DAT density was calculated with binding po-
tential (DAT-BP) using regions of interests (ROI) bilaterally drawn 
in the striatum (STR) and the occipital cortex (OCC- background). 
BP was calculated with the formula striatum (STR–OCC)/OCC. 
This protocol is already published elsewhere8.
Statistical analysis 
The correlation of clinical data between groups of patients 
with gene mutations was analyzed using Fisher’s exact test and 
chi-square test for categorical variables and non-paired Student’s 
t-test for continuous variables (parametric data). A 5% signifi-
cance level was set and p<0.05 was considered significant. The 
descriptive and statistical analyses were performed using Pris-
ma software program 3.0. 
The study was approved by UNIFESP-EPM and IIEP-HIAE Re-
search Ethics Board.
results
Table 1 summarizes the main clinical and epidemiolog-
ical characteristics of patients studied. Of 119 patients as-
sessed, 13 had mutations in either PARK2 (n=9) or PARK8 
genes (n=4). Since a couple of PARK2 patients were con-
sanguineous, the actual frequency of mutation found in 
our study was 10.1% (12/118). Most patients studied were 
women, especially in PARK8 group. Age at symptom on-
set was 32.4±11.3 years and 40.4±7.1 years in PARK2 and 
PARK8 groups, respectively. Both groups had a disease 
course of more than 10 years at the time of genetic test-
ing. In PARK2 group, 77% of patients had family history 
of PD compared to 50% in PARK8 group. Consanguinity 
was seen in PARK8 group only (75%). Of PD risk factors 
selected for this study, 100% of patients in PARK2 group 
and 50% in PARK8 group met the criteria for the variables 
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studied. The first symptom reported in both groups was 
resting tremor, most commonly affecting the hand/fore-
arm. The majority of patients took L-DOPA (100% and 75% 
in PARK2 and PARK8 groups, respectively). The rate of dys-
kinesia was 66% and 100% in PARK2 and PARK8 groups, re-
spectively. The mean time between L-DOPA use and dys-
kinesia onset was 4.2 years (n=6) in PARK2 patients com-
pared to 4 years (n=3) in PARK8 group.
A statistical comparison of clinical characteristics be-
tween PARK2 and PARK8 groups did not show any signifi-
cant differences as shown in Table 1.
Among those exposed to environmental risk factors, 
they were mostly exposed to rural living or well water 
drinking during their first and second decades of life. Ex-
posure to other products (pesticides, herbicides or organ-
ic solvents) and smoking occurred mainly during their sec-
ond and third decades of life. Well water drinking was sig-
nificantly more prevalent (p=0.004) in EOPD compared to 
controls. On Table 2 we detailed the mutations we found 
on both groups of patients with PARK2 and 8.
Table 3 shows the results of the binding potential 
(DAT-BP) of [99mTc] TRODAT-1 SPECT in 2 patients (1 in 
Table 1. Clinical characteristics of Brazilian Parkinson’s disease (PD) patients with mutations in either PARK2 or 
PARK8 genes. 
PARK2 PARK8 PARK2 vs. PARK8
Patients (n) n=9/119 n=4/119
Female-to-male ratio 1.75 4 p=1.0; NSa
Age at symptom onset1 32.4±11.3 years 40.4±7.1 years p=0.19; NSb
Disease course1 15.3±11.4 years 10.2±10.4 years p=0.75; NSb
Family history of PD 7/9; 77% 2/4; 50% p=0.6; NSa
Consanguinity 0/9; 0% 3/4; 75% p=0.06; NSa
Risk factors for PD 9/9; 100% 2/4; 50% p=0.25; NSa
Site of first symptom Hand/forearm n=6/9
Foot/leg n=4/9
Head n=1/9
Hand/forearm n=4/4
Foot/leg n=1/4
Head n=0/4
p=0.57;NSc
First symptom2 T n=7/9
R n=2/9
B n=0/9
Mixed n=2/9
T n=2/4
R n=0/4
B n=1/4
Mixed n=1/4
p=0.25; NSc
L-DOPA use? 9/9 3/4 p=0.55; NSa
Dyskinesia due to L-DOPA? 6/9 3/3 p=0.51; NSa
Time to L-DOPA-dyskinesia 4.2 years (n=6) 4 years (n=3) p=0.7; NSb
Dyskinesia severity3 M n=3
Mo n=1
S n=2
M n=0
Mo n=3
S n=0
p=0.56; NSb
1Mean±Standard deviation; 2T, resting tremor; R, rigidity; B, bradykinesia and/or I, postural instability; 3M, mild; Mo, moderate; 
S, severe; aFisher’s exact test; bNon-paired Student’s t-test; cChi-square test.
Table 2. Detailed description of mutations found in the patients 
studied.
Gene Exon/
Intron
Nucleotide / Mutated Protein
1 PARK2 EX 1 EX1del (het)/without traduction
2 PARK2 EX 2 156_157insT (het)/D53X*
3 PARK2 EX 2 156_157insT (het)/D53X*
4 PARK2 EX 3 EX3del (het)/N58QfsX39
5 PARK2 EX 3 EX3del (het)/N58QfsX39
6 PARK2 EX 3 EX3del (het)/N58QfsX39
7 PARK2 EX 3
EX 6
EX3del (het)/N58QfsX39
A633T (hom)/K211N
8 PARK2 EX 11 EX11del(het)/A390EfsX6
9 PARK2 IN 11 1286-3G>C(hom)/G429EfsX5
10 PARK8 EX 41 G6055A (het)/G2019S
11 PARK8 EX 41 G6055A (het)/G2019S
12 PARK8 EX 41 G6055A (het)/G2019S
13 PARK8 EX 41 G6055A (het)/G2019S
EX, exon; IN, intron; het, heterozigous; hom, homozigous.
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PARK2 and 1 in PARK8 group) compared to a healthy con-
trol, matched by age and gender.
disCussion
In recent years the knowledge on the etiology of PD 
has gained momentum with advances in molecular ge-
netics. Families with autosomal dominant disease forms 
and pathogenesis associated to the presence of Lewy 
bodies have been evidenced to be related to alpha-sy-
nuclein gene (PARK1)9. Other autosomal dominant forms 
of PD have been associated to LRRK2 gene (PARK8) and 
have been largely studied in recent years due to its high 
frequency of occurrence10,11. Autosomal recessive forms 
with EOPD have also been described associated to PARKIN 
(PARK2), DJ-1 (PARK6) and PINK-1 genes (PARK7)3. All these 
genetic mutations lead to abnormalities in proteins (e.g, 
ubiquitin), oxidative stress, and mitochondria and today it 
can be assumed that PD comprises a heterogeneous group 
of diseases with a wide range of clinical and pathological 
presentations.
Of all patients assessed in our study, only patients 
with mutations in PARK2 and PARK8 genes are described 
here, since tests are still ongoing with DJ-1 and PINK-1. 
Of 119 patients studied, 9 had mutation in PARK2 and 4 
in PARK8 gene, a frequency of mutation of 10.1% in these 
two genes only.
PARK2, a gene for autosomal recessive juvenile parkin-
sonism, has been first described in patients in Japan. The 
gene locus for this form of parkinsonism was mapped in 
6q25.2-27 chromosome12. PARK2 patients develop EOPD 
around the age of 20–30 and show distinct clinical char-
acteristics compared to idiopathic PD (slow progress, dy-
stonia at onset involving lower limbs, and dyskinesia after 
low-dose L-DOPA)13. Interestingly, pathologically, these pa-
tients do not have Lewy bodies12. PARKIN gene is believed 
to be associated to most sporadic cases developing before 
the age of 20 and nearly 25% of cases seen between the 
age of 20 and 35. The protein produced by PARKIN gene 
seems to be associated to protein ubiquitination, which 
acts as a ligase in the proteasome-ubiquitin system, elimi-
nating abnormal or mutant proteins. When they accumu-
late, seemingly they are cytotoxic and cause cell injury14. 
In PARK2 group of our study, their main characteristics 
were EOPD, long disease course, and common family his-
tory of PD but no case of consanguinity in first-degree an-
cestors was found. Their first symptom was resting tremor 
developing in hand/forearm. Of 9 patients who reported 
L-DOPA use, 66% developed dyskinesia, which was report-
ed after on average 4.2 years of drug use compared to 4 
years in PARK8 group. The most frequent mutation found 
was Ex3 deletion (Table 2).
Those with mutation in PARK2 gene are more com-
monly seen among EOPD patients. While many patients 
have family history of PD, as seen in our study, sporadic 
cases have been also reported developing at the age of 
40 years12-14. Their clinical presentation can be similar to 
idiopathic PD but they remarkably have dystonia in lower 
limbs, which was not seen in our group. Disease progres-
sion is often slower than in idiopathic PD but they tend to 
develop early-onset dyskinesia after low-dose L-DOPA12-14. 
The rate of dyskinesia (66%) found in our study is more 
characteristically seen in LOPD patients. 
Mutations in PARK8 gene are more frequently de-
scribed in LOPD patients, and they are either sporadic or 
familial10,11. They seem to be clinically and pathologically 
undistinguishable from idiopathic PD. The protein pro-
duced by the mutation in LRRK2 gene is called dardarin 
(the protein encoded by LRRK2 gene is called dardarin, 
and not by the mutation). Five different mutations have 
been described associated to this gene and the G2019S 
is the most common15. They are clinically very similar to 
sporadic cases of PD. They usually develop in the sixth 
decade of life and progress with complications due to 
L-DOPA use similar to sporadic disease. They can show a 
wide range of pathology presentations including disease 
associated to Lewy bodies, nigral degeneration and tau 
Table 3. TRODAT-1 SPECT binding potential (DAT-BP) in PARK2 and PARK8 patients compared to a sex- and age-matched 
healthy control subject.
Age at 
SPECT (y)
Disease 
duration (y)
Off 
H&Y
On total 
UPDRS
BP R 
caud
BP R 
put
BP L 
caud
BP L 
put
PARK2 36; F 11 3.0 51 0.80 0.45 0.73 0.50
PARK8 43; F 11 3.0 60 0.85 0.66 0.85 0.38
control 39; F NA NA NA 1.11 0.97 0.97 0.85
PARK2/control 27.63% 59.13% 34.47% 54.63%
PARK8/control 23.15% 12.73% 12.64% 0.08%
NA, non-applicable; H&Y, modified Hoehn & Yahr scale; UPDRS, unified Parkinson’s disease rating scale; BP, binding potential; R, right; L, left; 
caud, caudate; put, putamen.
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protein aggregation (PSP-like)14,15. Very recently it has been 
shown to express different phenotypes, like corticobasal 
syndrome and primary progressive aphasia16.
In our study, the main characteristics of PARK8 group 
were EOPD especially affecting women, long disease 
course, and non-relevant family history of PD though 
75% of patients had first- or second-degree consanguin-
ity. Their first symptom was resting tremor affecting the 
hand/forearm and all 3 patients who took L-DOPA devel-
oped dyskinesia. The most frequent mutation we found 
on PARK8 gene was the G2019S (Table 2).
Mutations in LRRK2 gene are the most common cause 
of monogenetic PD in patients with LOPD, cases are evenly 
distributed in both men and women but they have family 
history of autosomal dominant inheritance. This mutation 
has variable penetrance and it is thus the most frequently 
seen in sporadic cases of PD. Its clinical presentation is 
similar to idiopathic PD, it usually develops after the age 
of 40 with predominance of psychiatric symptoms3. 
It should be noted that patients with mutation in PAR-
KIN gene associated to G2019S mutations (PARK8) have 
recently been identified, which suggests digenic transmis-
sion of DP17. However, in our study, we did not find any 
similar cases. 
Molecular imaging studies assessing dopaminergic and 
even non-dopaminergic systems have now been used as 
biomarkers for PD18. We recently reviewed data on mo-
lecular imaging techniques in patients with genetic forms 
of PD (PARK1, 2, 6, 7 and 8) and clinically unclear cases of 
parkinsonism19-21. Neuroimaging data on PARK2 and PARK8 
patients show a pattern similar to the sporadic forms of 
PD, except for post-synaptic involvement with greater 
DAT loss in the early stages of disease and slower progres-
sion in PARK2 patients. Data from the patients we scanned 
showed greater difference in the PARK2 patient when com-
pared to a matched control. Further studies with larger 
samples are needed to further evaluate these differences.
A sample of these patients herein studied, comprising 
72 EOPD patients, was detailed studied for genetic char-
acteristics and risk factors of PD showing that well water 
drinking exposure represents a risk factor for EOPD and the 
PARK2 coding polymorphism Val380Leu might be interact-
ing with environmental factors acting as a disease modifier7.
The present study had some limitations: small number 
of genetic cases and SPECT scans and selection bias, where 
there were included EOPD patients with higher prevalence 
of mutations. The 10% frequency of mutation found in 
our study would probably be lower in a group of patients 
with late-onset Parkinson’s disease, i.e., the younger the 
patients with PD the more likely they have mutations. It 
should be stressed that we are currently testing PARK6 or 
PARK7 mutations in our sample. PARK1 mutation has not 
been investigated due to its low prevalence.
In conclusion, in our group of PARK2 and PARK8 pa-
tients, the frequency of mutation was 10.1%, predomi-
nantly in women. These patients had long disease course 
(around 10 years) and high rates of dyskinesia after L-
DOPA use (especially in those with PARK8 mutation), and 
tremor was the first symptom seen in all cases. Compared 
to PARK2 patients, PARK8 patients did not have a relevant 
family history of PD. SPECT results showed significant dif-
ferences between patient vs. control, which were more 
pronounced between PARK2 vs. control. 
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